From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in head & neck
In the ADJORL1 study, the efficacy and safety of nivolumab were investigated as adjuvant therapy in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) following salvage surgery. All participants
The GORTEC 2014-04 trial sought to assess the efficacy of omitting chemotherapy after Stereotactic Ablative Radiotherapy (SABR) in first-line treatment for metastatic head and neck cancer patients. The study enrolled
In-depth stories about head & neck
Several presentations at ESMO2023 highlighted significant advancements in the field of head and neck cancer research.
In the GORTEC2014-04 “OMET” trial, researchers investigated the escalation and de-escalation treatment strategies for
LIBRETTO-531, a phase 3 trial, was designed to establish the optimal first-line regimen for advanced RET-mutant MTC. Experts are deliberating the necessity of a large-scale global phase 3 study, especially
The research of Dr Natasha Honoré, medical oncologist at UC Louvain, Brussels focuses on the utilization of circulating tumour DNA (ctDNA) for the detection of minimal residual disease in patients
Head & neck poster selection
Dr Rachel Galot, medical oncologist at Cliniques Universitaires Saint-Luc in Brussels, presented the results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM), a phase II study of monalizumab and
With the educational support of: